STOCK TITAN

Teladoc (TDOC) legal chief nets shares as awards vest, sells portion for taxes

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Teladoc Health, Inc. insider Adam C. Vandervoort, the company’s Chief Legal Officer and Secretary, reported equity compensation vesting and related share sales. On June 1, 2026, restricted stock units and performance stock units converted on a one-for-one basis into a total of 14,928 shares of common stock. On June 2, 2026, he sold 7,906 shares of common stock at $7.627 per share to satisfy the tax withholding obligation tied to these vesting awards. Following these transactions, Vandervoort directly owned 110,261 shares of Teladoc common stock.

Positive

  • None.

Negative

  • None.
Insider Vandervoort Adam C
Role CHIEF LEGAL OFFICER, SECRETARY
Sold 7,906 shs ($60K)
Type Security Shares Price Value
Sale Common Stock 7,906 $7.627 $60K
Exercise Performance Stock Units 426 $0.00 --
Exercise Restricted Stock Units 5,350 $0.00 --
Exercise Restricted Stock Units 9,152 $0.00 --
Exercise Common Stock 426 $0.00 --
Exercise Common Stock 5,350 $0.00 --
Exercise Common Stock 9,152 $0.00 --
Holdings After Transaction: Common Stock — 110,261 shares (Direct, null); Performance Stock Units — 2,979 shares (Direct, null); Restricted Stock Units — 16,050 shares (Direct, null)
Footnotes (1)
  1. Performance stock units convert to shares of TDOC common stock on a one-for-one basis. Restricted stock units convert to shares of TDOC common stock on a one-for-one basis. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance stock unit and restricted stock unit awards. The performance stock units vest as to one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter. On March 1, 2026, the reporting person earned 5,107 performance stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter. On March 19, 2024, the reporting person was granted 64,200 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments beginning on June 1, 2025. On March 1, 2025, the reporting person was granted 109,832 restricted stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.
Shares sold 7,906 shares Common stock sold on June 2, 2026
Sale price $7.627 per share Price for 7,906 common shares sold
Shares acquired via vesting 14,928 shares Common shares from RSU and PSU conversion on June 1, 2026
Post-transaction holdings 110,261 shares Common shares directly owned after transactions
Exercise transactions 3 exercises, 14,928 shares Derivative exercises of RSUs and PSUs
Restricted stock units financial
"Restricted stock units convert to shares of TDOC common stock on a one-for-one basis."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Performance stock units financial
"Performance stock units convert to shares of TDOC common stock on a one-for-one basis."
Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.
tax withholding obligation financial
"Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance stock unit and restricted stock unit awards."
open-market sale financial
"Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Vandervoort Adam C

(Last)(First)(Middle)
C/O TELADOC HEALTH, INC.,
155 E 44TH ST, SUITE 1700

(Street)
NEW YORK NEW YORK 10017

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Teladoc Health, Inc. [ TDOC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CHIEF LEGAL OFFICER, SECRETARY
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/01/2026M426A(1)103,665D
Common Stock06/01/2026M5,350A(2)109,015D
Common Stock06/01/2026M9,152A(2)118,167D
Common Stock06/02/2026S7,906(3)D$7.627110,261D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Performance Stock Units(1)06/01/2026M426 (4) (4)Common Stock426(5)$02,979D
Restricted Stock Units(2)06/01/2026M5,350 (6) (6)Common Stock5,350$016,050D
Restricted Stock Units(2)06/01/2026M9,152 (7) (7)Common Stock9,152$064,070D
Explanation of Responses:
1. Performance stock units convert to shares of TDOC common stock on a one-for-one basis.
2. Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.
3. Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance stock unit and restricted stock unit awards.
4. The performance stock units vest as to one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.
5. On March 1, 2026, the reporting person earned 5,107 performance stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.
6. On March 19, 2024, the reporting person was granted 64,200 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments beginning on June 1, 2025.
7. On March 1, 2025, the reporting person was granted 109,832 restricted stock units, vesting one-third on March 1, 2026, with the remainder vesting in eight substantially equal quarterly installments thereafter.
Remarks:
/s/ Adam C. Vandervoort06/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Teladoc (TDOC) report for Adam C. Vandervoort?

Adam C. Vandervoort reported equity awards vesting into common shares and a related share sale. On June 1, 2026, restricted and performance stock units converted into 14,928 Teladoc common shares, followed on June 2, 2026 by a tax-related sale of 7,906 shares.

How many Teladoc (TDOC) shares did Adam C. Vandervoort sell in this Form 4?

He sold 7,906 Teladoc common shares. The sale occurred on June 2, 2026 at a price of $7.627 per share and was specifically described as covering the tax withholding obligation associated with recently vested equity awards.

At what price were Teladoc (TDOC) shares sold in Adam C. Vandervoort’s Form 4 filing?

The reported sale price was $7.627 per Teladoc common share. This price applied to 7,906 shares sold on June 2, 2026, with the transaction identified as a sale to satisfy tax withholding obligations arising from vesting restricted and performance stock units.

How many Teladoc (TDOC) shares does Adam C. Vandervoort hold after these transactions?

After the reported transactions, Adam C. Vandervoort directly owned 110,261 Teladoc common shares. This post-transaction holding reflects both the conversion of restricted and performance stock units into shares and the subsequent sale of a portion of those shares for tax withholding.

What equity awards vested for Adam C. Vandervoort in the latest Teladoc (TDOC) Form 4?

Restricted stock units and performance stock units vested and converted into Teladoc common shares. Footnotes state both award types convert to common stock on a one-for-one basis, with 14,928 underlying shares of common stock delivered in connection with these vesting events.